10-K: AptarGroup Reports 5% Sales Growth, Strategic Acquisitions in 2025

AptarGroup, a global leader in dispensing and drug delivery solutions, reported a 5% increase in net sales to $3.78 billion for fiscal year 2025, driven by strong Pharma and Closures segment performance and strategic acquisitions.

Summary

• Reported net sales increased 5% to $3.78 billion in 2025, up from $3.58 billion in 2024.
• Core sales, which exclude acquisitions and changes in foreign currency rates, increased by 2% in 2025.
• Net income increased 5% to $392.8 million, and reported earnings per share (diluted) increased 7% to $5.89.
• Returned $485.8 million to shareholders through share repurchases and dividends during 2025.
• Capital expenditures decreased year over year, ending at approximately 7% of sales.
• The Pharma segment's net sales increased 6% (3% core sales), driven by strong volume growth and royalty increases in prescription drug, injectables, and active material science solutions.
• The Beauty segment's net sales increased 7% (2% core sales), primarily due to stronger tooling sales, despite softer demand in the fragrance, facial skincare, and color cosmetics (F&F) market.
• The Closures segment's net sales increased 2% (1% core sales), with strong product sales in the food and beverage markets.
• Adjusted EBITDA margin remained consistent at 21.6% for both 2025 and 2024.
• Interest expense increased by $8.8 million to $52.7 million in 2025, due to an increase in both the amount and average interest rate of debt.
• A gain of $26.5 million was recognized from the remeasurement of the equity method investment in BTY upon increasing beneficial ownership to 80%.
• Repurchased approximately 1.5 million shares for $175.0 million during the fourth quarter of 2025.
• The Board approved a new share repurchase authorization of up to $600.0 million on February 3, 2026, replacing previous authorizations.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a solid performance, demonstrating consistent growth in net sales and earnings, strong shareholder returns, and strategic acquisitions. However, some segment-specific challenges and increased costs temper the overall positive outlook.

Positives

• Reported net sales increased 5% to $3.78 billion in 2025.
• Net income increased 5% to $392.8 million in 2025.
• Reported earnings per share (diluted) increased 7% to $5.89 in 2025.
• The Pharma segment's core sales increased 3%, driven by increased demand for emergency medicine, central nervous system solutions, and robust GLP-1 component sales.
• The Closures segment's core sales increased 1%, with strong product sales in salad dressing, spreads, food protection, functional drinks, and dairy applications.
• Returned $485.8 million to shareholders through share repurchases and dividends in 2025.
• Achieved the 32nd consecutive year of paying an annually increasing dividend.
• A new share repurchase authorization of up to $600.0 million was approved by the Board on February 3, 2026.
• Realized a $26.5 million gain from the remeasurement of the equity method investment in BTY.
• Maintains a strong financial position with the ability to generate cash flow from operations.
• Recognized as one of the World's Top Female-Friendly Companies by Forbes for 2025, 2024, 2023, and 2022.
• Recognized by the Women's Forum of NY for having 50% female board directors in 2025.
• Named one of Barron's 100 Most Sustainable Companies for 2025, marking the seventh consecutive year.
• Named to CDP's Supplier Engagement Assessment (SEA) A-list for the fifth consecutive year in 2024.
• Recognized as one of America's Climate Leaders 2024 by USA Today and one of TIME Magazine's World's Most Sustainable Companies 2025.
• Named one of America's Most Responsible Companies 2026 by Newsweek for the seventh year.
• Maintained a Platinum Sustainability Rating with EcoVadis since 2021.
• Management concluded that internal control over financial reporting was effective as of December 31, 2025.

Negatives

• Cost of sales as a percentage of net sales increased to 62.8% in 2025 from 62.2% in 2024, attributed to a mix of lower margin applications in Pharma and Beauty, operational inefficiencies, and increased input costs.
• The Beauty segment's Adjusted EBITDA decreased approximately 1% to $158.8 million, with its margin declining to 12.1% from 13.0%, due to a less favorable product mix, lower tooling margins, supplier disruptions, manufacturing inefficiencies, and higher tariff costs.
• Core sales to the consumer health care market within the Pharma segment declined 8%.
• Core sales to the F&F market within the Beauty segment decreased 4% due to softer demand for prestige fragrance technologies and facial skincare products.
• North America experienced weaker indie brand skincare demand, contributing to a lack of sales growth in the Beauty segment for that region.
• Interest expense increased by $8.8 million in 2025 to $52.7 million, driven by higher debt amounts and increased average interest rates.
• Net cash provided by operations decreased to $569.999 million in 2025 from $643.413 million in 2024, primarily due to the timing of income tax payments.
• Wrote off $2.1 million of software development costs during 2025.
• Experienced a $1.0 million negative impact from foreign currency and a $1.8 million negative impact from changes in pension expense on net other income in 2025 compared to 2024.

Risks

• Deterioration in economic conditions, including inflation, rising interest rates, or a recession, could materially adversely impact business and operating results by leading to postponed spending, order cancellations, increased accounts receivable defaults, inventory/supply challenges, and pricing pressures.
• Consumer demand for customer products and shifting consumer preferences are unpredictable and could negatively impact demand for Aptar's products.
• Geopolitical conditions, trade disputes, international boycotts and sanctions, political and social instability, acts of war, or terrorist activity could disrupt operations, making manufacturing or delivery difficult or more expensive, affecting supply chains, and indirectly impacting demand for products.
• Significant tariffs or other restrictions imposed on foreign imports by the U.S. and related countermeasures could increase raw material costs, disrupt global supply chains, and reduce demand for products.
• Increased global cybersecurity threats and more sophisticated, targeted computer crime, as well as failures or disruptions of information technology systems, pose risks to data confidentiality, availability, and integrity, potentially leading to compromise of information, operational disruptions, and legal liability.
• Employee retention or labor cost inflation could disrupt business, and the loss of a substantial number of employees or key management could make it difficult to manage and meet objectives.
• Strong global competition, including competitors' design innovation or ability to provide more sustainable products, could lead to market share decline.
• A fixed cost structure combined with potentially lower revenues in difficult market conditions may negatively impact results and gross margins.
• Inability to adequately source materials, especially from single suppliers for some Pharma segment components, or from single manufacturing locations, could adversely impact product delivery.
• A material failure or disruption at one or more manufacturing facilities could adversely affect the ability to generate sales and meet customer demand, leading to lost sales, delayed deliveries, and increased costs.
• Global health crises, epidemics, and pandemics may adversely affect business, financial condition, and results of operations.
• The success or failure of customer products, particularly in the pharmaceutical market, may materially affect operating results and financial condition, especially if products are not approved or successful after significant development investment.
• Bankruptcy, insolvency, or other credit failure of customers could lead to inability to collect receivables, adversely affecting net sales and increasing bad debt expense.
• Higher raw material costs and other inputs (plastic resin, rubber, metal, transportation, energy) and an inability to offset these with price increases may materially adversely affect operating results and financial condition.
• Disputes with unions or strikes/work stoppages by unionized workers or suppliers could significantly disrupt operations.
• Failure to achieve expected benefits from restructuring initiatives could adversely affect business and operations, potentially leading to unforeseen costs or reduced employee productivity.
• Integration of acquisitions or significant capital investments failing to generate expected returns could cause financial performance to suffer.
• Foreign currency translation and transaction risks may materially adversely affect operating results due due to movements in exchange rates, particularly for the euro, Chinese yuan, Brazilian real, Argentine peso, Mexican peso, Swiss franc, and other Asian, European, and Latin American currencies.
• Goodwill impairment: The $1.08 billion in goodwill at December 31, 2025, is subject to annual impairment testing, and changes in future business conditions could require write-downs that would reduce operating income.
• Subject to a variety of laws and regulations (anti-corruption, trade, sanctions, competition, data privacy, FDA), and changes in or failure to comply with these could have an adverse impact on reputation, business, and results of operations.
• Exposure to lawsuits and claims, including product liability, intellectual property infringement, commercial, employment, tort, business interruption, and regulatory investigations, which may result in substantial costs or operational disruptions.
• Challenges to, or the loss of, intellectual property rights could have an adverse impact on the ability to compete effectively.
• Government regulation on environmental matters, including recycling or environmental sustainability policies (e.g., plastic waste, PFAS bans, tethered caps), could impact business by forcing faster development of alternatives or increasing costs.
• Future government regulations of healthcare cost containment policies may impact pharmaceutical sales.
• Interest rate volatility could increase borrowing costs as fixed-rate debt obligations become due.
• Subject to changes in tax rates, adoption of new tax legislation or rules (e.g., OECD Pillar Two), or exposure to additional tax liabilities, which could materially and adversely affect financial condition and operating results.
• Loss of royalty revenues due to contract expirations could negatively impact sales and margins.
• Global climate change and legal, regulatory, or market measures to address climate change may negatively affect business, operations, and financial results (physical risks, carbon taxes, increased costs for sustainable materials).
• Ownership by certain significant stockholders (four institutional stockholders owning between 5% and 11%) could put downward pressure on the stock price if they decide to sell significant volumes.

Future Outlook

Aptar expects earnings per share for the first quarter of 2026, excluding restructuring expenses, changes in the fair value of equity investments, and acquisition-related costs, to be in the range of $1.13 to $1.21, based on an effective tax rate range of 21% to 23% and spot rates at the end of December for all currencies. The company anticipates 2026 operating cash flow will be more than sufficient to fund working capital needs, capital investments (expected to be in the range of $260.0 million to $280.0 million), and outstanding purchase commitments. Financing cash outlays of approximately $156.5 million are expected in 2026 for debt obligations, to be covered by cash on hand or additional borrowings. Aptar also expects to continue paying a regular quarterly dividend at a similar level in 2026.

Management Comments

• Aptar is a global leader in the design and manufacturing of drug and consumer product dosing, dispensing and protection technologies.
• Aptar's strategy is focused on strengthening its position as a global provider in drug and consumer dosing, dispensing and protection technologies while delivering long-term value to our customers and stockholders.
• We believe we are well positioned to withstand temporary slowness in any one particular region or market.
• We believe our competitive advantages include our consistent high levels of innovation, quality, regulatory, pharma services, geographic diversity, financial strength and reliability and breadth of products and services.
• We believe Aptar is a leader on corporate environmental ambition, action and transparency worldwide as proven by our 'A' letter grade on the CDP climate change assessment and our 'B' letter grade on the CDP water assessment.
• Management believes the resolution of these claims and lawsuits will not have a material adverse effect on our financial position or results of operations or cash flows.
• Given our current level of leverage and our ability to generate cash flow from operations, we believe we are in a strong financial position to meet our operational commitments in the foreseeable future.

Industry Context

StockSavvy.ai notes that AptarGroup's continued focus on sustainable product platforms and digital health solutions aligns with broader industry trends towards eco-friendly packaging and advanced patient care technologies. The growth in the Pharma segment, particularly in injectables (GLP-1 components) and active material science, reflects the robust demand in specialized healthcare markets. The challenges in the Beauty segment's F&F market, however, indicate a competitive landscape where consumer preferences for prestige and facial skincare products are shifting, requiring continuous innovation and adaptation. The company's global manufacturing strategy, aiming to produce in the region of sale, is a common industry approach to mitigate supply chain risks and enhance responsiveness.

Comparison to Industry Standards

• AptarGroup's recognition as one of Barron's 100 Most Sustainable Companies for seven consecutive years, its CDP 'A' grade for climate change assessment, and 'B' grade for water assessment, along with being named one of TIME Magazine's World's Most Sustainable Companies 2025 and Newsweek's America's Most Responsible Companies 2026, indicate strong performance relative to global sustainability benchmarks.
• The company's 50% female board directors in 2025, as recognized by the Women's Forum of NY, positions it favorably against many industry peers in terms of gender diversity in corporate governance.
• The 32nd consecutive year of increasing dividends demonstrates a consistent commitment to shareholder returns, a benchmark for mature, stable companies.
• The company's competitive advantages in innovation, quality, regulatory compliance, and geographic diversity are critical in the highly competitive packaging and drug delivery markets, where peers like West Pharmaceutical Services, Inc. and Berry Global Group, Inc. also operate.

Management Changes

Corporate Governance

Legal Proceedings

• AptarGroup, Inc. and Aptar France SAS filed a lawsuit on March 25, 2025, in the U.S. District Court for the Southern District of New York against ARS Pharmaceuticals, Inc. and ARS Pharmaceuticals Operations, Inc., alleging misappropriation of trade secrets and breach of contractual confidentiality obligations. Aptar seeks injunctive relief and damages.
• ARS Pharmaceuticals Operations, Inc. filed an antitrust lawsuit on September 29, 2025, in the U.S. District Court for the Southern District of California against Aptar, alleging violations of U.S. competition laws related to the supply of certain components and seeking injunctive relief and damages.
• Nemera La Verpillire SAS filed parallel patent infringement actions in May 2025 in Mannheim Regional Court, Germany, and Paris Judicial Court, France, against Aptar and certain subsidiaries, alleging infringement by Aptar's ophthalmic product. An EPO hearing on October 2, 2025, invalidated Nemera's main patent claim while allowing an amended claim to continue. The infringement proceedings are ongoing.
• Subject to loss contingencies from custom duties assessments, with claims worth approximately $11.0 million in principal and $22.0 million to $23.0 million for interest and penalties. No liability is recorded as of December 31, 2025, due to uncertainty in settlement probability and appeal timing.

Related Party Transactions

• Prior to consolidation on July 28, 2025, Aptar had purchases of $7.4 million from BTY for the year-to-date period. For the year ended December 31, 2024, purchases from BTY totaled $11.4 million. Approximately $2.1 million was due to BTY as of July 28, 2025, and $2.5 million as of December 31, 2024, included in accounts payable, accrued and other liabilities.

Stakeholder Impact

• Shareholders: Benefited from $120.8 million in dividends paid and $365.0 million in share repurchases in 2025, with a new $600.0 million repurchase authorization approved, indicating a strong commitment to returning capital.
• Employees: The company invests in talent acquisition and development, offers competitive pay and benefits, and focuses on well-being, safety, engagement, and leadership succession. Approximately 56% of the total employee population is covered by collective bargaining agreements.
• Customers: Aptar provides innovative solutions and end-market expertise, focusing on convenience, product differentiation, and sustainability. However, some segments experienced softer demand, and price competition remains high.
• Suppliers: Dependence on single-source suppliers for certain Pharma components poses a risk. The company utilizes a supply chain finance program, with $32.0 million due to participating suppliers at year-end 2025.
• Creditors: Total debt increased to $1.48 billion, and the Net Debt to Net Capital ratio increased to 28.6%, but the company maintains a strong financial position and expects to meet its obligations.
• Environment/Community: Demonstrates a strong commitment to sustainability, with validated science-based targets for emissions reduction, increased renewable electricity, and product designs focused on recyclability and reduced material use. Recognized as a leader in environmental ambition and transparency.

Next Steps

• The Annual Meeting of Stockholders is scheduled for May 6, 2026.
• Expects Q1 2026 earnings per share (excluding certain items) to be in the range of $1.13 to $1.21.
• Anticipates 2026 capital investments to be in the range of $260.0 million to $280.0 million.
• Expects to continue paying a regular quarterly dividend at a similar level in 2026.
• The Board approved a new share repurchase authorization of up to $600.0 million on February 3, 2026, replacing previous authorizations.
• Ongoing legal proceedings with ARS Pharmaceuticals and Nemera are continuing.
• Continued efforts to mitigate climate risks and further the low-carbon economy, including annual data assurance for sustainability reporting.
• Transitioning lotion pumps to all plastic solutions to advance the sustainability agenda.
• Developing new solutions with alternative propellants for pressurized metered-dose inhalers (pMDIs) to reduce greenhouse gas emissions.
• Evaluating the impact of ASU 2024-03 (Disaggregation of Income Statement Expenses) on disclosures for fiscal years beginning after December 15, 2026.

Key Dates

Recommendation

AptarGroup demonstrates consistent financial performance with growth in sales and net income, supported by strategic acquisitions and a strong commitment to shareholder returns through dividends and share repurchases. The Pharma segment shows robust growth, aligning with favorable industry trends. However, challenges in the Beauty segment, increased operating costs, and higher interest expenses present headwinds. The company's strong sustainability credentials and effective corporate governance are positives, but ongoing competitive pressures and geopolitical risks warrant a cautious approach. Given the mixed performance across segments and the current macroeconomic uncertainties, a 'Hold' recommendation is appropriate for investors seeking stable, long-term growth with a balanced risk profile.

Keywords

AptarGroup, ATR, Annual Report, SEC Filing, Financial Results, Dispensing Technologies, Drug Delivery, Packaging Solutions, Pharma Segment, Beauty Segment, Closures Segment, Sustainability, Acquisitions, Share Repurchase, Dividends, Corporate Governance, Risk Factors, EBITDA, Net Sales, Net Income, EPS, Capital Expenditures, Debt, Intellectual Property, Cybersecurity, Environmental Regulations